Connect with us

Lifestyle

Ayurcann Holdings Is Leading in The Canadian Cannabis Industry By Creating New Ventures

mm

Published

on

A Toronto-based company is making their mark in the Canadian cannabis sector by creating a niche in the booming market.

Ayurcann Holdings Corp has a unique business model that provides post-harvest solutions for licensed producers. Their B2B processing facility located in the GTA  offers many services for Canadian licensed cannabis producers. These services include extraction, white label manufacturing and refining cannabis into oil.

Ayurcann has created an exclusive Marketplace where they sell oil-infused products, which include vape products, topicals and tinctures (herbal extracts) thereby giving licensed producers an opportunity to sell their product.

The company was founded by Igal Sudman and Roman Buzaker in 2018 who was granted his license in 2020. His company went public earlier this year and now can be found on the stock market (AYUR).

“As an entrepreneur to recognize opportunities is paramount to success, being able to run a profitable and successful growing company in the cannabis space has not been done until Ayurcann,” Sudman said.

With Sudman’s 20 years of experience in founding and developing businesses featured on Canadian Profit 50 and knows what it means to be a visionary.

We had a chance to speak with Sudman and discuss what differentiates Ayurcann from other companies and his new ventures within the Ayurcann Marketplace. 

Can you tell us what differentiates your company from other cannabis companies?

“We are focused on value and growth. We understand that running a successful company is being focused on the bottom line and being responsible to create and sell products that the consumers demand, our ability to run a profitable and growing company has not been done in the cannabis space in Canada.” 

What is the Ayurcann Marketplace and how can the public access the marketplace?

The marketplace is a patient only portal where medical patients with prescriptions can learn more about the cannabis products available, interact directly with our patient support staff and select value life enhancing cannabis products. It is available online now. Ayurcann takes its responsibility very seriously when it comes to patients, their security, privacy, and requirements. To use the marketplace, a potential patient needs to register by filling out the Patient Registration Form and be able to provide their medical documents. An Ayurcann Marketplace patient support staff then verifies and confirms the provided information with the health practitioner that prescribes the use of cannabis and if confirmed, approves the use and purchase ability of the patient. “

Can you go into detail about Ayurcann Marketplace and how it helps potential licensed producers? 

“The ability to offer a variety of products directly to patients, create your own marketing and set your own prices helps other Licensed producers to move products quickly and more profitability then dealing with only one monopolized system in the recreational space.”

How is the marketplace bettering patients who are using medical marijuana?

The marketplace is a patient only portal where medical patients with prescriptions can be educated and learn more about the various cannabis products available, interact directly with our patient support staff and select enhancing cannabis products. It is available online now. It helps concentrate the offerings from a variety of producers throughout the country, providing selection and better value to patients, like an Amazon model.”

What are some opportunities or gaps you saw when it comes to providing patients who need to use medical marijuana for medicinal purposes? 

“Current structure of patient uses, and purchase patterns works where the patients deal with one Licensed producer and their offerings only, an Amazon model like Ayurcann marketplace enables for a more competitive and wider selection for the patients and enhances their ability to be more selective and save money on their cannabis consumption.”

Can you go into details what are the six new products from Fuego and your new Xplor brand? 

“We make recreational and medical based products that bring a wide variety of brands into the Canadian marketplace, The Fuego brand specializes in a high potency recreational use vape products and the Xplor brand is focused on the oil-based tincture products for medical use.”

Can you tell us what’s the Xplor brand and the concept behind this new brand? 

“We felt that having a medical based product and brand will distinguish us from the current market offerings. The Xplor is intended to provide a variety of products with THC and CBD in high potency dosage for medical patients.”

Michelle has been a part of the journey ever since Bigtime Daily started. As a strong learner and passionate writer, she contributes her editing skills for the news agency. She also jots down intellectual pieces from categories such as science and health.

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Lifestyle

Kat Marie Alvarez: Where Innovation Meets Regulation

mm

Published

on

Regulation is often thought of as a limitation, yet in healthcare, it also serves as a foundation for building models that endure. For Kat Marie Alvarez, Founder and CEO of KATALYST & CO, the framework of rules established by agencies like CMS (Centers for Medicare and Medicaid) and the OIG ( office of the Inspector General) create opportunities to design systems that are compliant, ethical, and transformative. Her approach demonstrates that regulation can be a platform for innovation when it is interpreted with both technical rigor and vision.

Kat’s 25-year career reflects this philosophy. A former nurse who advanced into executive leadership and strategy, she has led $2.7B+ P&L operations, advised on over $5B in healthcare transactions, and guided value based organizations including Innovacare, Cano Health, WellMed, Centene, and Humana through periods of exponential scaling. Her perspective combines clinical, financial, and regulatory experience, giving her a unique ability to design structures that support integrity and accountability while driving measurable outcomes.

Turning Statutes into Strategy

For Kat, regulation serves as a framework for building smarter and more ethical models. She interprets CMS guidance and OIG rules as levers for innovation, using them to advance integrity and accountability. With the CMS V28 risk adjustment model, Alvarez refined coding practices, strengthened clinical documentation, and structured risk frameworks that reward accuracy and elevate standards of care. In addressing RADV audits, she crafted strategies that protect stakeholders while keeping patient outcomes at the forefront. She aligns compliance, cost, and care in equal measure. Her current work as a contributor to the CMS IDea Challenge, an initiative focused on strengthening the foundation of trust in our system, further echoes her commitment to advancing regulations in ways that unlock innovation while safeguarding the integrity of care.

Her interpretive approach brings discipline and vision to every challenge. She engages stakeholders to redesign workflows that meet regulatory requirements and enhance the patient experience. Each policy becomes a mechanism to strengthen accountability and operational precision, shaping a system that is both compliant and humane.

Innovation Built Within Boundaries

At KATALYST & CO, this interpretive approach is carried into every project. Kat has integrated predictive analytics and AI-driven tools into care models, with safeguards that ensure interventions remain clinician-led and ethically sound. For example, AI flags in chronic disease management are connected to human-led actions that improve patient care. The result is a model that benefits from technology while preserving accountability and clinical integrity.

Staffing and infrastructure provide another example of her philosophy in action. By leveraging offshore BPO operations in Latin America, Asia, and Eastern Europe, KATALYST & CO extends capacity for health plans and providers. These expansions are carefully designed to meet data security, licensure, and jurisdictional requirements, ensuring that global reach is paired with local compliance. It is a system that balances scale with responsibility.

The Art of Influence Through Alignment

Kat often describes her role as translating complexity into clarity. Whether she is working with payers, providers, or investors, she builds consensus by grounding ambitious strategies in the language of statute. Value-based care models, utilization management programs, and clinical frameworks are designed to prove compliant ROI for stakeholders while maintaining patient focus.

Her approach begins with people. In integrations, partnerships, and platform builds, she respects legacy strengths, listens to frontline voices, and creates systems that are not only efficient but also trusted. This ensures that compliance does not feel like restriction, but like a structure that supports innovation and adoption.

Redefining the Future of Compliance and Care

KATALYST & CO is scaling with $10M in initial funding, expanded international operations, and a growing advisory portfolio. Under Kat’s leadership, the firm is showing how regulation can be a foundation for both innovation and durability. She demonstrates that lasting progress in healthcare is achieved by leaders who know how to design systems that are bold, ethical, and deeply human.

By approaching regulation as a guide rather than a limitation, Kat Alvarez is building models that prove compliance and innovation can move forward together. Her formula ensures that the future of healthcare is shaped not only by ambition, but also by trust and responsibility.

Continue Reading

Trending